SATB2 and MDM2 Immunoexpression and Diagnostic Role in Primary Osteosarcomas of the Jaw
Authors:
- Adepitan A. OwoshoAdepitan A. Owosho
- Adeola M. LadejiALAdeola M. Ladeji
- Olufunlola M. AdesinaOAOlufunlola M. Adesina
- Kehinde E. AdebiyiKAKehinde E. Adebiyi
- Mofoluwaso A. OlajideMOMofoluwaso A. Olajide
- Toluwaniyin OkunadeTOToluwaniyin Okunade
- Jacob PalmerJPJacob Palmer
- Temitope KehindeTKTemitope Kehinde
- Jeffrey A. VosJVJeffrey A. Vos
- Grayson ColeGCGrayson Cole
- Kurt F. SummersgillKSKurt F. Summersgill
Open Access
- 30 December 2021
- journal article
- research article
- Published by MDPI AG in Dentistry Journal
- Vol. 10 (1) , 4
Abstract
Primary osteosarcomas of the jaw (OSJ) are rare, accounting for 6% of all osteosarcomas. This study aims to determine the value of SATB2 and MDM2 immunohistochemistry (IHC) in differentiating OSJ from other jawbone mimickers, such as benign fibro-osseous lesions (BFOLs) of the jaw or Ewing sarcoma of the jaw. Certain subsets of osteosarcoma harbor a supernumerary ring and/or giant marker chromosomes with amplification of the 12q13–15 region, including the murine double-minute type 2 (MDM2) and cyclin-dependent kinase 4 (CDK4) genes. Special AT-rich sequence-binding protein 2 (SATB2) is an immunophenotypic marker for osteoblastic differentiation. Cases of OSJ, BFOLs (ossifying fibroma and fibrous dysplasia) of the jaw, and Ewing sarcoma of the jaw were retrieved from the Departments of Oral Pathology and Oral Medicine, Faculty of Dentistry, Obafemi Awolowo University and Lagos State University College of Medicine, Nigeria. All OSJ retrieved showed histologic features of high-grade osteosarcoma. IHC for SATB2 (clone EP281) and MDM2 (clone IF2), as well as fluorescence in situ hybridization (FISH) for MDM2 amplification, were performed on all cases. SATB2 was expressed in a strong intensity and diffuse staining pattern in all cases (11 OSJ, including a small-cell variant, 7 ossifying fibromas, and 5 fibrous dysplasias) except in Ewing sarcoma, where it was negative in neoplastic cells. MDM2 was expressed in a weak to moderate intensity and scattered focal to limited diffuse staining pattern in 27% (3/11) of cases of OSJ and negative in all BFOLs and the Ewing sarcoma. MDM2 amplification was negative by FISH in interpretable cases. In conclusion, the three cases of high-grade OSJs that expressed MDM2 may have undergone transformation from a low-grade osteosarcoma (LGOS). SATB2 is not a dependable diagnostic marker to differentiate OSJ from BFOLs of the jaw; however, it could serve as a valuable diagnostic marker in differentiating the small-cell variant of OSJ from Ewing sarcoma of the jaw, while MDM2 may be a useful diagnostic marker in differentiating OSJ from BFOLs of the jaw, especially in the case of an LGOS or high-grade transformed osteosarcoma.Keywords
This publication has 42 references indexed in Scilit:
- Osteosarcoma: A Comparison of Jaw versus Nonjaw Localizations and Review of the LiteratureSarcoma, 2013
- Osteosarcoma of the Jaws: Factors Influencing PrognosisJournal of Oral and Maxillofacial Surgery, 2011
- Roles of SATB2 in Osteogenic Differentiation and Bone RegenerationTissue Engineering Part A, 2011
- The Molecular Pathogenesis of Osteosarcoma: A ReviewSarcoma, 2011
- Cleft lip and palate: understanding genetic and environmental influencesNature Reviews Genetics, 2011
- Small Deletions of SATB2 Cause Some of the Clinical Features of the 2q33.1 Microdeletion SyndromePLOS ONE, 2009
- Satb2 Haploinsufficiency Phenocopies 2q32-q33 Deletions, whereas Loss Suggests a Fundamental Role in the Coordination of Jaw DevelopmentThe American Journal of Human Genetics, 2006
- SATB2 Is a Multifunctional Determinant of Craniofacial Patterning and Osteoblast DifferentiationCell, 2006
- MDM2 — master regulator of the p53 tumor suppressor proteinGene, 2000
- Mdm2 promotes the rapid degradation of p53Nature, 1997